Alterity Therapeutics has outlined three priorities for 2026 following the successful completion in 2025 of a Phase II trial of ATH434 in Multiple System Atrophy. Alterity outlines three priorities ...

A student-run organization at the University of Missouri, Rockin’ Against Multiple Sclerosis, is hosting philanthropic events to raise money for the Multiple Sclerosis Institute while leaving a ...

SEOUL, Jan. 28 (UPI) --North Korean leader Kim Jong Un oversaw the test-firing of an upgraded large-caliber multiple rocket system, state-run media reported Wednesday. Kim said the test held "great ...

The FDA has granted 510(k) clearance to Medtronic for its MiniMed “Go Smart” multiple daily injection system — the first smart MDI system to automatically integrate insulin dosing and glucose data ...

Please provide your email address to receive an email when new articles are posted on . The MiniMed Go app received FDA 510(k) clearance for people with type 1 or type 2 diabetes requiring insulin.

In the 1997 film Tomorrow Never Dies, legendary secret agent James Bond drives an E38-generation BMW 750iL equipped with machine guns, rockets, and other spy-worthy goodies. 28 years later, news comes ...

Early one morning, while checking on a slumbering patient at the Center for Sleep Medicine, Erik St. Louis, M.D., noticed something peculiar. The patient, a woman in her early 60's, had started ...

HONOLULU — A novel “moderate-affinity iron chaperone” known as ATH434 (Alterity Therapeutics) may slow disease progression in patients with multiple system atrophy (MSA), new research suggested. The ...

Takeda has given up on an AstraZeneca-partnered neurological disorder program after the therapy flunked a phase 2 study. The Japanese pharma had been evaluating the alpha-synuclein antibody, called ...

Ionis Pharmaceuticals Inc. ((IONS)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...